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Nuclear Factor kappa B (NF-kB) is a key transcriptional regulator that plays important
roles in the pathogenesis of hepatic inflammation and fibrosis in chronic liver diseases.
NF-kB activation leads to production of pro-inflammatory and fibrogenic cytokines.
Glycyrrhizin (GL) is reported to suppress liver fibrosis and cirrhosis. Omega-3 fatty acids
(u-3) play an anti-inflammatory role and they are reported to decrease hepatic injury in
Thioacetamide (TAA) fibrotic model. We investigated the effects of GL and u-3 on liver
inflammation and fibrosis in rats and clarified the effects of these natural compounds on
NF-kB level. 50 male Wistar rats randomized to 5 groups: Control group and 4 groups
received TAA 200 mg/kg i.p. twice weekly for 8 weeks: TAA group, GL group (received GL
25 mg/kg daily by oral tube), u-3 group (received u-3150 mg/kg daily by oral tube),
(GLþu-3) group (received similar combined doses of both natural compounds). GL and
u-3 alone or in combination protected the liver from TAA hepatotoxic effects as they
significantly decreased serum AST activity and serum total bilirubin level, they also
significantly increased serum albumin and total protein levels. The hepatoprotective
effects of GL and u-3 were confirmed by the histopathological analysis as they signifi-
cantly reduced the necroinflammatory scores and the extent of fibrosis. GL and u-3
significantly decreased liver malondialdehyde level (P < 0.005), liver NF-ƙB level
(P < 0.005) and its tissue expression as detected by immunohistochemistry. In conclu-
sion, glycyrrhizin and omega-3 fatty acids alone or in combination have potent anti-
inflammatory, anti-oxidant and anti-fibrotic effects.
Copyright 2014, Mansoura University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).om (N.F. Abo El-Magd), lailaeissa2002@yahoo.com (L.A. Eissa).
ra University.
sity. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
/licenses/by-nc-nd/4.0/).
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Chronic liver diseases are an increasing cause of morbidity
and mortality in more developed countries [1]. Most chronic
liver diseases, including viral hepatitis (B and C), alcoholic
liver disease, and biliary diseases, ultimately lead to liver
fibrosis [2]. Liver fibrosis is the wound-healing response of the
liver to many causes of chronic injury. Iterative liver injury
causes inflammatory damage, matrix deposition, paren-
chymal cell death and angiogenesis leading to progressive
fibrosis. The scarmatrix typically accumulates very slowly but
once cirrhosis is established the potential for reversing this
process is decreased and complications develop [3].
Without effective treatments at an early stage, reversible
liver fibrosis will lead to irreversible cirrhosis and hepatocel-
lular carcinoma (HCC) [4]. Supplementation with antioxidants
which reduce oxidative stress is an effective strategy for pre-
venting liver fibrosis [5]. The development of targeted thera-
pies for themanagement and treatment of hepatitis requires a
better knowledge of the immune response mechanisms
involved in the pathogenesis of liver disease [6]. Anti-fibrotic
therapies are emerging that can slow, halt or reverse fibrosis
progression [3].
Glycyrrhizin (GL) is the main bioactive component of lico-
rice root extract. GL is a glycosylated saponin composed of one
molecule of glycyrrhetinic acid and two molecules of glucur-
onic acid [7]. GL is reported to be used in chronic hepatitis
resulted from different causes, such as viral infections, toxin
exposure and ischemic-reperfusion injury [8]. GL has potent
anti-inflammatory properties which thought to play a vital
role in its hepatoprotective effects [9]. GL is reported to bind
directly to high mobility group box 1 (HMGB1) so it decreases
the HMGB1 concentration [10]. HMGB1 is a highly conserved
protein released by injured or dying cells as a result for
pathogenic products. HMGB1 plays a central role in the path-
ogenesis of both sterile and infectious inflammation [11].
HMGB1 may trigger an inflammatory response via activation
of TLR-4 (Toll like receptor-4) pathway which activates Nu-
clear Factor-kappa B (NF-kB), so it enhances the production of
tumor necrosis factor ɑ (TNF-ɑ), interleukine-1b (IL-1b) and
nitric oxide [12]. Experimental strategies that selectively target
HMGB1 effectively prevent activation of innate immunity and
inflammation so protect different tissues against injury and
damage [11].
Omega-3 fatty acids (u-3) such as eiocosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) are bioactive dietary
compounds. Marine-derived food sources such as fatty fish,
seaweed, shellfish, microalgae and krill are rich in u-3 [13,14].
u-3 supplements are reported to be used in hepatic injury and
steatosis [15]. EPA andDHAprotected against arachidonic acid
produced pro-inflammatory molecules through conversion to
less inflammatory mediators, so EPA and DHA have anti-
inflammatory effects [16]. u-3 are also reported to alter the
production of inflammatory mediators such as chemokines,
growth factors and matrix proteases [17].
Hepatitis is modulated by several mechanisms such as
inflammatory signaling pathway and innate immunity
response [18]. Inflammation produces by an innate host de-
fense mechanism against infections and a variety of tissueinjuries. The inflammatory process passes through distinct
stages, including acute, adaptive, and resolution, and more-
over, inflammation may become a chronic condition as in
autoimmune diseases [19]. The NF-kB system plays a vital role
in regulating the innate immunity responses and cellular
stress in different cell types [19,20]. NF-kB remains in the
cytoplasm in unstimulated cells as a complex with inhibitory-
kappaB proteins (I-kB) that prevent their translocation to the
nucleus. During cell activation, I-kB is phosphorylated and
dissocaited, which exposes the nuclear translocation sites of
NF-kB leading to translocation of NF-kB to the nucleus and
DNA binding [21,22]. NF-kB composes of p65/p50 heterodimers
in macrophages and binds to the promoter region of various
pro-inflamamatory genes leading to gene transactivation. NF-
kB plays an important regulatory role in hepatic macrophage
expression of pro-inflammatory mediators [22].
The aim of this study was to evaluate the potential hep-
atoprotective effect of GL and u-3 alone or in combination
against TAA-induced liver fibrosis in rats, and to elucidate its
underlying molecular mechanism through its effect on NF-kB
and oxidative stress.2. Materials and methods
2.1. Drugs and chemicals
Thioacetamide and Glycyrrhizin (Glycyrrihizic acid ammo-
nium salt) from licorice (Glycyrrhiza Glabra) root (Sigma-
eAldrich: Sigma, St. Louis, MO, USA). Omega-3 fatty acids
containing EPA and DHA in a 3:2 ratio (Lifeplan: Elizabethan
Way, Lutterworth, United Kingdom).
2.2. Animals
Fifty Male SpragueeDawley rats weighing (180e200 g) were
purchased from “Egyptian Organization for Biological Prod-
ucts and Vaccines”, Giza, Egypt. Animalswere housed and had
free access to standard rat food and tapwater for oneweek for
acclimatization. The animal care and experiments described
in this study were complied with “Research Ethics Commit-
tee” Faculty of Pharmacy, Mansoura University, Egypt which
are in accordance with “Principles of Laboratory Animal Care”
(NIH publication No. 85-23, revised 1985).
2.3. Induction of liver fibrosis
Liver fibrosis was induced according to the method of Esmat
et al. [23] and Furtado et al. [24]. Fourty two male Sprague-
Dawly rats were intraperitoneally (i.p.) injected with freshly
prepared TAA (200 mg/kg of body weight) in 0.2 ml sterile
saline twice weekly (days 2 and 6) for 8 consecutive weeks.
2.4. Experimental design
Rats were distributed randomly to five groups: Control group
(8 rats): injected i.p. with 0.2 ml sterile saline twice weekly
(days 2 and 6) for 8 consecutive weeks, TAA group (12 rats):
TAA-induced fibrotic group, GL group (10 rats): hepatic fibrosis
treated with GL (25 mg/kg/day by oral tube dissolved in
Fig. 1 e Effect of thioacetamide (TAA) (200 mg/kg twice
weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg daily) and
omega-3 fatty acids (u-3) (150 mg/kg daily) alone or in
combination on serum ALT and AST activities. Values:
(Mean ± SE). **P < 0.005 vs. Control group. #P < 0.05,
##P < 0.005 vs. TAA group. $$P < 0.005 vs. GL group.
¥P < 0.05, ¥¥P < 0.005 vs. u-3 group.
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rats): hepatic fibrosis treated with u-3 (150 mg/kg/day by oral
tube) [26,27] for 8 weeks started with TAA, GL þ u-3 group (10
rats): hepatic fibrosis treatedwith a combination of GL andu-3
(received similar doses) with TAA.
2.5. Collection of blood samples and liver tissues
At the end of the experiment, rats were fasted for 12 h then
5 ml blood samples were taken from the retro-orbital punc-
ture under light ether anesthesia. The clotted blood samples
were centrifugated at 5000 rpm for 5 min for serum separa-
tion. Serum was divided into aliquots for analysis. Animals
were sacrificed and the liver dissected out, rinsed in ice-cold
phosphate buffer saline (PBS) PH 7.4 and blotted dry on a fil-
ter paper. A small part from right lobe of liver was cut and
fixed in 10% phosphate-buffered formalin (pH 7.2) for histo-
pathological examination. Part of the remaining liver tissues
were homogenized in cold PBS then centrifuged at 5000 rpm
for 15 min. The supernatant was removed for assay of
malondialdehyde (MDA). While other part of the liver tissues
were homogenized in cold PBS, with ultrasonic homogenizer
then centrifuged at 5000 rpm for 15 min. The supernatant
removed for assay of liver NF-kB. Serum samples and super-
natant from liver homogenates were stored at 80 C for
biochemical analysis.
2.6. Biochemical analysis
 Serum was used for determination of ALT, AST activities,
serum total bilirubin, total protein and albumin levels
using commercial kits from Biodiagnostic (Cairo, Egypt).
 Liver tissue homogenate was used for assaying lipid per-
oxidation by measuring MDA using commercial kit from
Biodiagnostic (Cairo, Egypt) and assaying Rat NF-kB using
ELISA kit from Mybiosource (MBS722386) (San Diego, CA,
USA).2.7. Histopathological examination
Phosphate-buffered formalin fixed liver tissues were
embedded in paraffin, then they were cut into 4 mm thick
sections and they were stained with hematoxylin and eosin
(H&E) and Masson's trichrome for histopathological
examination.
2.8. Assessment of necroinflammatory activity grades
Liver samples stained with (H&E) were assessed for total and
individual activity parameters guided by Ishak's activity index
[28]. Classified according to the following parameters: inter-
face hepatitis (piecemeal necrosis) (P1eP4), confluent necrosis
(C0eC5), focal lobular necrosis and degeneration (FN0eFN4),
and portal inflammation (PI1ePI4).
2.9. Quantification of fibrotic areas
Quantitative analysis of collagen fiber deposition in Masson's
trichromestained liver tissueswasperformedbymorphometricanalysis [29]. Imageswere takenbyadigital cameramounted on
a BX51 Olympus optical microscope (Olympus Corporation,
Tokyo, Japan). The NIH Image software was used for extraction
and analyzing of collagenous areas stained with masson's tri-
chrome. The extent of fibrosis was expressed as the percentage
of fibrotic area relative to the total tissue area.2.10. Immunohistochemical detection of NF-kB
For immunohistochemistry, mouse NF-kB/65 Rabbit Poly-
clonal Antibody antibodies (Thermo Fisher Scientific, CA,
USA) were applied to deparaffinized and rehydrated sections.
After removal of the unbound primary antibodies by rinsing
with PBS, slides were incubated with secondary antibody. The
analysis of antibody binding was performed with a dia-
minobenzidine (DAB) kit, and hematoxylin was used as the
counterstain. The slides were then observed by light micro-
scopy. Expression of NF-kB was detected in the cytoplasm of
liver tissue and inflammatory cells at the areas of inflamma-
tion and fibrosis (according to manufacturer instructions).
Expression in different groupswas compared as regards to the
distribution and intensity (compared to endothelium as an
internal control) and distribution of positive areas.2.11. Statistical analysis
All the results were expressed as the mean ± Standard error
(SE). One-way analysis of variance (ANOVA) followed by
bonferroni test was used for analyzing statistically significant
Table 1 e Effect of thioacetamide (TAA) (200 mg/kg twice weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg), omega-3 fatty
acids (u-3) (150 mg/kg) alone or in combination on serum total bilirubin, albumin and total protein levels. Values:
(Mean ± SE).
Control TAA GL u-3 GLþu-3
Number of animals 8 rats 8 rats 8 rats 8 rats 10 rats
Total bilirubin (mg/dl) 0.158 ± 0.029 0.964 ± 0.074** 0.184 ± 0.010## 0.228 ± 0.025## 0.208 ± 0.046##
Albumin (g/dL) 3.267 ± 0.070 2.593 ± 0.050** 3.045 ± 0.044## 3.027 ± 0.050## 3.258 ± 0.112##
Total protein (g/dl) 7.101 ± 0.087 5.648 ± 0.157** 6.541 ± 0.172# 6.616 ± 0.154# 7.200 ± 0.273##
*P < 0.05, **P < 0.005 vs. control group.
#P < 0.05, ##P < 0.005 vs. TAA group.
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considered significant. The analysis was carried out using
Statistical Package for the Social Sciences (SPSS) version 18.
Graphs were performed with GraphPad Prism V 5.02 (Graph-
Pad Software Inc., San Diego, CA, USA).3. Results
3.1. Effect of GL and u-3 on liver function
Thioacetamide produced liver fibrosis characterized by
significant increase in serum ALT and AST activitiesFig. 2 e Effect of thioacetamide (TAA) (200 mg/kg twice
weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg daily) and
omega-3 fatty acids (u-3) (150 mg/kg daily) alone or in
combination on (A) liver MDA level and (B) liver NF-kB level.
Values: (Mean ± SE). **P < 0.005 vs. Control group.
##P < 0.005 vs. TAA group.compared with control group (P < 0.005), while treatment
with GL or u-3 had no significant change in ALT activity, but
significantly decreased AST activity compared with TAA
group (P < 0.05). Treatment with GL and u-3 combination
significantly decreased serum ALT and AST activities
compared with TAA group (P < 0.05, P < 0.005), respectively,
and significantly decreased serum ALT and AST activities
compared with either GL or u-3 groups (P < 0.05), as shown
in (Fig. 1).Fig. 3 e Effect of thioacetamide (TAA) (200 mg/kg twice
weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg daily) and
omega-3 fatty acids (u-3) (150 mg/kg daily) alone or in
combination on (A) liver necroinflammatory score and (B) %
ratio between fibrotic area to total tissue area. Values:
(Mean ± SE). **P < 0.005 vs. Control group. #P < 0.05,
##P < 0.005 vs. TAA group.
Fig. 4 e The left vertical panel showed marked necroinflammation in the TAA group that became reduced after combined
treatment with (GL þ u-3) more than single treatment (arrows around bridging necrosis). The middle panel showed
increased collagen deposition in TAA group with its reduction after combined treatment (GL þ u-3) more than single
treatment (arrows around fibrous bridges). The right panel showed increased NF-kB expression colocalized at the same
areas of necroinflammation and bridging fibrosis in TAA group with much reduced expression with combined treatment
(GL þ u-3) than single treatment. Thioacetamide (TAA), Glycyrrhizin (GL), Omega-3 fatty acids (u-3) and (GL þ u-3) groups
(magnification £100).
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crease in serum total bilirubin level compared with control
group (P < 0.005).While treatment with GL and u-3 alone or
in combination produced highly significant decrease in
serum total bilirubin level compared with TAA group
(P < 0.005) and there are no significant difference between
GL, u-3 and GLþu-3 groups and the control group, as
shown in Table 1.Thioacetamide affected the liver function significantly as it
decreased the ability of liver to synthesize the albumin and
other proteins as the serum levels of albumin and total protein
decreased significantly in TAA group compared with control
group (P < 0.005). While treatment with GL and u-3 alone or in
combination protected the liver as the serum levels of albu-
min and total protein increased significantly compared with
TAA group (P < 0.005, P < 0.05), respectively and there are no
Table 2 e Correlational analysis of the studied parameters.
AST activity Total bilirubin level Albumin level Total protein level Liver NF-kB level
AST activity (r) 1 0.581a 0.731a 0.591a 0.626a
Total bilirubin level (r) 0.581a 1 0.701a 0.669a 0.875a
Albumin level (r) 0.731a 0.701a 1 0.594a 0.685a
Total protein level (r) 0.591a 0.669a 0.594a 1 0.519a
Liver NF-kB level (r) 0.626a 0.875a 0.685a 0.519a 1
a Correlation is significant at P < 0.001 level.
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and the control group, as shown in Table 1.3.2. Effect of GL and u-3 on hepatic lipid peroxidation
Thioacetamide caused a significant increase in hepatic MDA
content in comparison to control group (P < 0.005), while
treatment with GL and u-3 alone or in combination signifi-
cantly decreased the elevatedMDA levels compared with TAA
group (P < 0.005), as shown in (Fig. 2A).3.3. Effect of GL and u-3 on hepatic NF-kB concentration
Thioacetamide caused significant increase in the hepatic
concentration of NF-kB compared with control groupFig. 5 e Positive correlation between liver NF-kB level and (A) Liv
(r ¼ 0.787), (C) Liver % ratio between fibrotic area to total tissue(P < 0.005), while treatment with GL and u-3 alone or in
combination highly significantly decreased NF-kB level
compared with TAA group (P < 0.005) and there are no sig-
nificant difference between GL, u-3 and GLþu-3 groups and
the control group, as shown in (Fig. 2B).3.4. Effect of GL and u-3 on hepatic necroinflammatory
activity
Examination of TAA group showed moderate to severe nec-
roinflammatory activity with average scores of (14.5) with
marked piecemeal necrosis, zone 3 necrosis and multiple
portal central bridging necrosis, frequent apoptosis and focal
inflammation with moderate and marked portal inflamma-
tion. Treatment with GL and u-3 alone or in combinationer MDA level (r ¼ 0.883), (B) Liver necroinflammatory score
area (r ¼ 0.758) and (D) Serum AST activity (r ¼ 0.626).
Fig. 6 e Non-significant positive correlations between
serum ALT activity and (A) Liver NF-kB level (r ¼ 0.243), (B)
Liver necroinflammatory score (r ¼ 0.228) and (C) Liver %
ratio between fibrotic area to total tissue area (r ¼ 0.275).
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TAA reflected by reduction of necroinflammation to (10.3)
(p < 0.05), (10.5) (p < 0.05) and (9) (p < 0.005), respectively and
there are no significant difference between GL, u-3 and
GLþu-3 groups and the control group, as shown in (Fig. 3A
and Fig. 4, left vertical panel).
3.5. Effect of GL and u-3 on hepatic fibrosis
Thioacetamide increased amount of collagen deposition in
liver tissue stained with Masson's trichrome significantly,
while treatment with GL and u-3 alone or in combination
significantly protected the liver from this increase (P < 0.005)
and there are no significant difference between GL, u-3 and
GLþu-3 groups and the control group. So GL and u-3 alone or
in combination decreased the fibrotic areas and collagen
content significantly (Fig. 3B and Fig. 4, middle vertical panel).
3.6. Expression of NF-kB
Expression of NF-kB was increased in hepatic tissues of rats
injected with TAA that colocalized at the same areas ofincreased necroinflammation and fibrosis, while expression
of NF-kBwas reduced in hepatic tissues treatedwith GL andu-
3 alone or in combination compared with TAA group (Fig. 4,
right vertical panel).
3.7. The correlation analysis of studied parameters
The data in Table 2 and Figs. 5 and 6 show the correlation
analysis of all studied parameters. Liver NF-kB level positively
correlated with liver MDA level (0.883, P < 0.001), liver nec-
roinflammatory score (0.787, P < 0.001) and % ratio between
fibrotic area to total tissue area (0.0758, P < 0.001), as shown in
(Fig. 5). Also liver NF-kB level positively correlated with serum
AST activity (0.626, P < 0.001) and serum total bilirubin level
(0.875, P < 0.001). NF-kB level negatively correlated with serum
albumin level (0.685, P < 0.001) and serum total protein level
(0.519, P < 0.001), as shown in Table 2. Serum ALT activity
had non-significant positive correlation with liver NF-kB level
(0.243), liver necroinflammatory score (0.228) and liver % ratio
between fibrotic area to total tissue area (0.275) as shown in
(Fig. 6).4. Discussion
Liver fibrosis is considered as the main complication of
chronic liver diseases and a range of chronic inflammatory
diseases [2]. Chronic inflammation is followed by accumula-
tion of collagen which resulted from a cascade of events that
involves cytokines produced by both liver resident cells and
circulating immune cells. These inflammatory stimuli cause
activation of quiescent hepatic stellate cells (HSCs) to myofi-
broblast like cells to produce collagen [30,31]. When hepatic
fibrosis occurs, collagen (mainly types 1 and 3) proliferation
accounts for 50% of the total protein in fibrotic liver [32]. With
ongoing injury, fibrosis develops to bridging fibrosis with
nodule formation which ends with cirrhosis and HCC. So,
initial prevention of liver fibrosis is a critical strategy for
curing chronic liver diseases [31].
In our study, TAA intoxication caused an intense oxidative
stress as evident by the dramatic increase in the hepatic MDA
level. MDA is a toxic product of peroxidation of biological
membrane polyunsaturated fatty acids. Therefore the mea-
surement of MDA is used as an indicator of oxidative stress
[33]. TAA is a potent hepatotoxin, so it is used in producing
hepatic injury showed lesions similar to those seen in most
cases of human liver disease. TAA causes cytotoxic injury
through a two-step bioactivationmediated by themicrosomal
cytochrome P450 isozyme E1 and/or flavin-containing mono-
oxygenase systems. TAA converts to TAA-sulfoxide and
further to a reactive metabolite, TAA-S, S-dioxide, which
responsible for lipid peroxidation at the plasma membrane
level [34].
Glycyrrhizin and u-3 alone or in combination protected the
liver from the oxidative stress caused by TAA as they
decreased significantly the elevated liver MDA. GL and u-3 act
as scavengers of free radicals, so they decrease the oxidative
stress. A decrease of lipid peroxidation mediated oxidative
stress may be a potential and effective strategy for the pre-
vention and treatment of hepatic failure [35].
Fig. 7 e The proposed hepatoprotective mechanism of glycyrrhizin and omega-3 fatty acids in thioacetamide-induced
fibrosis in rats.
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by piecemeal necrosis, confluent necrosis, focal lytic necrosis,
apoptosis, focal inflammation and portal inflammation at the
tissue levels which reflected in our study by significant eleva-
tion of serum liver enzymes and bilirubin as well as increased
collagen deposition and fibrotic areas significantly. GL and u-3
aloneor in combinationprotected liver fromthis inflammation
at tissue levelwhich is reflected by significant increased serum
AST activity and serum bilirubin level, and decreased collagen
and fibrotic areas. These are evidence for the hepatoprotective
effect of GL and u-3 alone or in combination.
Glycyrrhizinandu-3groupsshowednosignificantchange in
ALT activities compared with TAA group. Also, there is no sig-
nificant correlation between ALT activity and both liver fibrosisand liver necroinflammatory score. Thesemay be explained as
enzyme activity does not reflect the severity of fibrosis and
there is no significant correlation between serum ALT activity
and histological activity [36]. In accordance to these results, our
observations indicated that: a decreased ALT activity in TAA
group may be a result of massive necrosis and late stage of
fibrosis, while decreasedALT activity in GL andu-3 groupsmay
be due to recovery, as decreasing ALT activity in hepatic injury
occur both with recovery and with massive necrosis [36,37].
We found that TAA caused a significant increase in liver
NF-kB concentration. GL,u-3 and their combination prevented
the increase in liver NF-kB concentration. So GL, u-3 and their
combination have a hepatoprotective effect through blocking
NF-kB pathway, since NF-kB plays a regulatory role in liver
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genesis predominantly in three different cellular compart-
ments by: (A) Regulating hepatocyte injury, the primary
trigger of fibrogenic responses in the liver; (B) Regulating in-
flammatory signals elicited in macrophages and other in-
flammatory cells in the liver and (C) Regulating fibrogenic
responses in HSCs [38].
Our results indicated positive correlations between liver
NF-kB level and both liver necroinflammatory score and liver
collagen deposition. So we suggested that NF-kB has a critical
role in the pathogenesis of fibrosis and necroinflammation
development in liver. NF-kB increased significantly in TAA
group, while the treatment with GL, u-3 or their combination
prevented the increase in NF-kB, so they prevented the
development of liver fibrosis and necroinflammation. We also
found a positive correlation between liver NF-kB level and
lipid peroxidation, so oxidative stress has a positive effective
role in liver inflammation and fibrosis in TAA group. The anti-
oxidant properties of GL and u-3 have also an effective role as
anti-inflammatory and anti-fibrotic.
Glycyrrhizin has a variety of pharmacologic effects such as
anti-inflammatory, antiviral, antioxidant, immunomodula-
tory, hepatoprotective and cardioprotective activities [39]. We
found that GL and u-3 have dramatic effects on NF-kB and
MDA, as they significantly decreased when compared with
TAA group. These resultsmay confirm the anti-inflammatory,
anti-fibrotic and anti-oxidant effects of either GL or u-3.
Studies supposed that GL binded to HMGB1 directly to sup-
press HMGB1-induced injury, inhibit TLR-4 pathway, lower
NF-kB concentration and inhibit the production of inflam-
matory cytokines [40e42]. u-3 reduced the inflammation by
lowering NF-kB concentration. Lowering NF-kB inhibited the
production of inflammatory cytokines including TNF-a and IL-
1b, reduced arachidonic acidederived eicosanoids and pro-
tected against oxidative stress [43,44]. Studies found that u-3
decrease the production of inflammatory proteins which may
be mediated by altered activation of key transcription factors
in regulating inflammatory gene expression, such as NF-kB
and peroxisome proliferator activated receptors (PPAR- ).
Both NF-kB and PPAR- may be regulated by u-3 [17,43].
Fig. 7 indicates our proposed hepatoprotective mecha-
nisms of GL and u-3 in TAA-induced fibrosis in rats. GL pro-
tected the liver from TAA-toxic effects through decreasing
liver NF-kB level which indicated the blocking HMGB1. It also
decreased the lipid peroxidation. Also, u-3 decreased NF-kB
level and the lipid peroxidation so they protected the liver
from TAA-toxic effects.
We found that GL, u-3 and their combination have high
protection potency against liver fibrosis as they decrease the
collagen deposition, fibrotic areas, oxidative stress, NF-kB
level and tissue expression, pro-inflammatory cytokines and
fibrogenic cytokines. We also found that the protection po-
tency of either GL or u-3 alone is the same as their combina-
tion against liver fibrosis.5. Conclusions
The results of the current study supported the potential role of
NF-kB in liver fibrosis and demonstrated that thehepatoprotective effect of glycyrrhizin and omega-3 fatty acids
alone or in combination against liver fibrosis as they decreased
both the fibrotic areas and the necroinflammatory scores. The
mechanism behind hepatoprotective effects of glycyrrhizin
and omega-3 fatty acids included suppression of oxidative
stress and Inhibition of NF-kB. So the hepatoprotective effects
of glycyrrhizin, omega-3 fatty acids and their combination
against TAA-induced fibrosis appear to be mediated via its
antioxidant, anti-inflammatory and anti-fibrotic properties.
We advise to fulfill some clinical studies on these natural
compounds as nutrient to protect against liver fibrosis.r e f e r e n c e s
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